FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.
Sitemap
Evrys Bio
3805 Old Easton Road
Doylestown, PA 18902
View the FCOI Policy pertaining to federally funded projects

Leave a Reply
Want to join the discussion?Feel free to contribute!